Search
Durlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigationalIt is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases. … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023.
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalAnti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified … by the presence of ANCAs in the serum.
Aprotinin
go.drugbank.com/drugs/DB06692ApprovedInvestigationalWithdrawnFor this use, it is typically administered by injection. … The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery.
Mixtures: ARTISS SOLUTIONS FOR SEALANT, DEEP FROZEN, Artiss Solutions for Sealant, Deep FrozenTemazepam
go.drugbank.com/drugs/DB00231ApprovedIn particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to … obtain the necessary rest required for medical recovery or scheduled maneuvers and operations [A175339].
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawn[A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawncholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … [A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453,L8459] It was first approved for use in the United States in 2014. … [A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459]
Cefmetazole
go.drugbank.com/drugs/DB00274ApprovedA semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been n...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseGlycopyrronium
go.drugbank.com/drugs/DB00986ApprovedInvestigationalVet approved[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers. … [L33105] Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium].
Categories: Drugs for Obstructive Airway Diseases, Drugs for Functional Gastrointestinal DisordersSofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalApproved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [DB00811] depending on the level of liver damage or cirrhosis [FDA Label]. … As a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use